Search company, investor...

Predict your next investment

RA Capital Management company logo
Advisory
FINANCE | Asset/Financial Management
racap.com

Investments

311

Funds

6

Partners & Customers

1

Service Providers

1

About RA Capital Management

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, and diagnostics. The firm provides seed funding to startups and leads private, IPO, and follow-on financings for its portfolio companies, thereby driving value creation from idea inception through commercialization.

Headquarters Location

200 Berkeley Street 18th Floor

Boston, Massachusetts, 02116,

United States

Want to inform investors similar to RA Capital Management about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing RA Capital Management

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find RA Capital Management in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Research containing RA Capital Management

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned RA Capital Management in 1 CB Insights research brief, most recently on Aug 5, 2021.

Latest RA Capital Management News

Carmot Therapeutics Raises $150M in Series E Equity Financing

May 31, 2023

Carrot Therapeutics , a Berkeley, CA-based clinical-stage biotechnology company, raised $150M in Series E funding. The round was led by Deep Track Capital with participation from 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, RA Capital Management, Millennium Management, TCGX, The Column Group, Venrock Healthcare Capital Partners and Willett Advisors. The company intends to use the funds to strengthen its broad portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis. Led by Heather Turner, Chief Executive Officer, Carmot Therapeutics is a clinical-stage biotechnology company that is focused on the discovery and development of disease-modifying therapies for people living with metabolic diseases including obesity and diabetes. The company uses Chemotype Evolution, a drug discovery platform, to identify novel incretin receptor signaling targets and develop a broad pipeline of therapeutics that have the potential to produce significant weight loss and improved glycemic control. It has three clinical candidates: CT-388 (once-weekly, dual GLP-1/GIP receptor modulator), CT-868 (once-daily, dual GLP-1/GIP receptor modulator) and CT-996 (oral, small molecule GLP-1 receptor agonist). FinSMEs 31/05/2023

RA Capital Management Investments

311 Investments

RA Capital Management has made 311 investments. Their latest investment was in Carmot Therapeutics as part of their Series E on May 5, 2023.

CBI Logo

RA Capital Management Investments Activity

investments chart

RA Capital Management Fund History

6 Fund Histories

RA Capital Management has 6 funds, including RA Capital Nexus Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/6/2021

RA Capital Nexus Fund III

$880M

1

10/21/2020

RA Capital Nexus Fund II

$99M

10

7/15/2019

RA Capital Nexus Fund

Subscribe to see more

Subscribe to see more

$99M

10

7/12/2019

RA Capital Nexus International Fund

$99M

10

RA Capital Healthcare Fund LP

Subscribe to see more

Subscribe to see more

10

Closing Date

10/6/2021

10/21/2020

7/15/2019

7/12/2019

Fund

RA Capital Nexus Fund III

RA Capital Nexus Fund II

RA Capital Nexus Fund

RA Capital Nexus International Fund

RA Capital Healthcare Fund LP

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$880M

$99M

$99M

$99M

Sources

1

10

10

10

10

RA Capital Management Partners & Customers

1 Partners and customers

RA Capital Management has 1 strategic partners and customers. RA Capital Management recently partnered with Xenomorph on July 7, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

7/5/2022

Vendor

United Kingdom

New York, Boston, and London – July 5, 2022. RA Capital selects Xenomorph for Bio-Tech and Financial Data Management - Xenomorph

Having completed an extensive selection process and subsequent proof of concept , RA Capital Management selected Xenomorph to deliver a comprehensive enterprise data management solution for their bio-tech and financial data needs .

1

Date

7/5/2022

Type

Vendor

Business Partner

Country

United Kingdom

News Snippet

New York, Boston, and London – July 5, 2022. RA Capital selects Xenomorph for Bio-Tech and Financial Data Management - Xenomorph

Having completed an extensive selection process and subsequent proof of concept , RA Capital Management selected Xenomorph to deliver a comprehensive enterprise data management solution for their bio-tech and financial data needs .

Sources

1

RA Capital Management Service Providers

1 Service Provider

RA Capital Management has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

RA Capital Management Team

10 Team Members

RA Capital Management has 10 team members, including current Founder, Managing Partner, Peter Kolchinsky.

Name

Work History

Title

Status

Peter Kolchinsky

Founder, Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Peter Kolchinsky

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Managing Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare RA Capital Management to Competitors

Sciety Logo
Sciety

Sciety is an investment syndicate that offers capital market services with a focus on life science. It specializes in investment, finance, market analysis, and more. It is based in Stockholm, Sweden.

K
Kjaya

Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

m
m2m Imaging

Corp.m2m Imaging, with offices in USA and Australia produce's high-definition imaging and work flow solutions for life science applications in the MRI, PET, CT and SPECT analytical, preclinical and clinical research environments. m2m's MRI coil and accessory portfolio consists of products that have provided solutions to enable otherwise unobtainable results for research applications all over the world.

O
Ost Medical

The company are a enterprise recognized in the enteral products industry as a manufacturer of high quality, yet cost-effective devices. The company supply products to domestic and international customers. The company also are a contract manufacturer focused on the development and production of equipment for the medical and life sciences industries. The company's organization is composed of individuals with years of industry experience. OST Medical has a strong commitment to the company's customers and the company are confident in the company's ability to meet customer expectations in quality, price and delivery.

Proterixbio Logo
Proterixbio

ProterixBio develops products to transform the management of chronic diseases.

O
Otothera Corporation

Otothera Corporation is a medical device company developing products to diagnose and treat the more than seven million severe tinnitus (constant ringing in the ears) sufferers in the US. The company was originally named AudioFusion. The company was a 2006 PTEN Growth Accelerator (GAP) winner.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.